Structural modification based on the diclofenac scaffold: Achieving reduced colitis side effects through COX-2/NLRP3 selective inhibition
- 17 February 2024
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 268, 116257
Abstract
No abstract availableKeywords
Funding Information
- Zhejiang University of Technology
- Natural Science Foundation of Zhejiang Province (LTGY23B020003, B23141480003, H4148230578)
This publication has 38 references indexed in Scilit:
- Non-steroidal anti-inflammatory drugs (NSAIDs), pain and aging: Adjusting prescription to patient featuresBiomedicine & Pharmacotherapy, 2022
- Inflammation: Biochemistry, cellular targets, anti-inflammatory agents and challenges with special emphasis on cyclooxygenase-2Bioorganic Chemistry, 2022
- Recent development on COX-2 inhibitors as promising anti-inflammatory agents: The past 10 yearsActa Pharmaceutica Sinica B, 2022
- Discovery of a series of ester-substituted NLRP3 inflammasome inhibitorsBioorganic & Medicinal Chemistry Letters, 2020
- True or false? Challenges and recent highlights in the development of aspirin prodrugsEuropean Journal of Medicinal Chemistry, 2020
- Design of balanced COX inhibitors based on anti-inflammatory and/or COX-2 inhibitory ascidian metabolitesEuropean Journal of Medicinal Chemistry, 2019
- Cyanidin-3-O-Glucoside Protects PC12 Cells Against Neuronal Apoptosis Mediated by LPS-Stimulated BV2 Microglial ActivationNeurotoxicity Research, 2019
- Structural alterations based on naproxen scaffold: Synthesis, evaluation of antitumor activity and COX-2 inhibition, and molecular dockingEuropean Journal of Medicinal Chemistry, 2018
- Regulation of IL-6 in Immunity and Diseases2016
- Cyclooxygenase‐2 Regulates NLRP3 Inflammasome‐Derived IL‐1β ProductionJournal of Cellular Physiology, 2014